Signaling Under Stress: Targeting the Glucocorticoid Receptor in Cancer
Melanie S. Flint, David M. O’Malley, Domenica Lorusso, Susan K. Lutgendorf, Alexander B. Olawaiye, Adrian M. Jubb, Premal H. Thaker · 2026
Read Signaling Under Stress: Targeting the Glucocorticoid Receptor in Cancer by Melanie S. Flint, David M. O’Malley, Domenica Lorusso, Susan K. Lutgendorf, Alexander B. Olawaiye, Adrian M. Jubb, Premal H. Thaker (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13434298.txt.
Description
Flint and colleagues reviewed in 2026 how signaling through the glucocorticoid receptor, the cell's receiver for stress hormones such as cortisol, helps solid tumors survive. How blocking it can restore drug power. Advanced cancer brings pain, distress, and treatment strain that stir this pathway, and many tumors use it to dodge cell death, grow, spread, hide from immunity, and resist therapy. Steroid drugs given for side effects can feed the same route.
Selective receptor blockers, in lab and animal work, team up with several drug classes, from taxane chemotherapy to hormone and immune therapies, partly by lowering two shield proteins that blunt chemotherapy. Randomized trials in platinum-resistant ovarian cancer confirmed better results when a blocker joined standard taxane treatment, and prostate cancer work shows the blockers can cut resistance to hormone therapy. The authors close with the open questions that must be settled before this strategy spreads.
Catalog record
| CREATOR | Melanie S. Flint, David M. O’Malley, Domenica Lorusso, Susan K. Lutgendorf, Alexander B. Olawaiye, Adrian M. Jubb, Premal H. Thaker |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 48 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |